3 hours BridgeBio Pharma (NASDAQ:BBIO) PT Lowered to $46.00 at Leerink PartnersMarketBeat
Leerink Partners decreased their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday.
X